IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
“A Comparative Study On Ruksha And Snigdha Virechana In The Management Of Amavata (Rheumatoid Arthritis )”

Author: MAHESH P, BM SUSHMA, RAVI SAHU, IMLIKUMBA, K B ROY, THAKKER N
Abstract: Amavata (Rheumatoid arthritis)is one of the most common Rheumatological problem and is most frequent joint disease with prevalence approximately 0.8% of the population (range 0.3to 2.1% ). Women are affected approximately three times more than men in India. This is the most common cause of locomotor disability in the elderly. On the other hand Ayurveda has realized this problem in ancient era and has enumerated various treatment modalities both internal and external, out of which one of the most important one remains Virechana Karma. 30 patients of Amavata (Rheumatoid arthritis) were randomly selected from the IPD of Panchakarma, SDM College of Ayurveda and Hospital, Hassan. These patients were divided in to two groups, i.e. in Group A the patients were subjected to Snigdha Virechanawith Pachana, Snehana, Vishrama Kala, Virechanwith Eranda Tailaand Samsarjana Krama was advised whereas and in Group B the patients received Pachana, Snehana, Vishrama Kala and Samsarjana Krama same as mentioned in the Group A, whereas for Virechana Trivrit Choorna 30gm along with Ushna Jala was given.In Snigdha Virechanagroup i.e. in Group A 66.6% of the patients had good improvement, 36.6% with moderate improvement and 6.6% with mild improvement. None of the patients was found unchanged. In Ruksa Virechana group i.e. in Group B 76.6% of the patients had moderate improvement and 3.3% with mild improvement. It is concluded that on comparing the effect of therapy, following conclusion may be drawn: Ruksha Virechana Group has provided better relief (percentage wise ) than Snigdha Virechana Group in most of the signs and symptoms of the disease.
Keyword: Virechana, Amavata, Snigdha Virechana,Ruksa Virechana,Ayurveda, Panchakarma, Rheumatic Arthritis.
DOI: https://doi.org/10.31838/ijpr/2020.12.01.034
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free